Medpace (MEDP) Projected to Post Earnings on Monday

Medpace (NASDAQ:MEDP) is anticipated to post its quarterly earnings results after the market closes on Monday, April 21st. Analysts expect Medpace to post earnings of $3.05 per share and revenue of $528.38 million for the quarter. Medpace has set its FY 2025 guidance at 11.930-12.690 EPS.Investors interested in participating in the company’s conference call can do so using this link.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, analysts expect Medpace to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Medpace Stock Up 5.5 %

Shares of NASDAQ:MEDP opened at $297.72 on Monday. The firm has a market capitalization of $9.00 billion, a PE ratio of 23.57, a P/E/G ratio of 3.81 and a beta of 1.46. The company has a 50-day moving average price of $323.58 and a two-hundred day moving average price of $334.47. Medpace has a twelve month low of $272.00 and a twelve month high of $459.77.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Leerink Partnrs upgraded Medpace to a “hold” rating in a research report on Monday, March 24th. Robert W. Baird upped their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Mizuho cut their price objective on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a research report on Wednesday, April 9th. Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They set a “market perform” rating and a $330.00 target price on the stock. Finally, Truist Financial lowered their target price on shares of Medpace from $347.00 to $333.00 and set a “hold” rating on the stock in a research note on Thursday. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus target price of $361.90.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.